Does tailoring really make a difference? : the development and evaluation of tailored interventions aimed at benzodiazepine cessation

evaluation of tailored interventions aimed at benzodiazepine cessation

Wolde, G.B. ten

Citation

Wolde, G. B. ten. (2008, September 18). Does tailoring really make a difference? : the development and evaluation of tailored interventions aimed at benzodiazepine cessation. Retrieved from https://hdl.handle.net/1887/13104

Version: Not Applicable (or Unknown)

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden Downloaded from: https://hdl.handle.net/1887/13104

Note: To cite this publication please use the final published version (if applicable).

General introduction

This chapter introduces benzodiazepine use and its associated problems. Although pharmacological treatment with benzodiazepines can be effective and may be the best treatment in certain categories of patients, in general, chronic use of benzodiazepines is not desirable. In addition, this chapter describes the studies that were conducted to investigate the problem of chronic use of benzodiazepines from a health psychological perspective.

This chapter also describes the development of an intervention to reduce chronic use of benzodiazepines by using the Precede/Proceed model as a theoretical framework.

G G G G G G G G

Ge e en e e e n n n ne n n n n e e e er r ra a a al l i l l i in n n n n nt tr t t t t r r r r ro o od o o o o o o o o o d du d d d d d d u uc u u u u u c c c c ct t ti t t t t t t i i i i i io o on o o o o o o n n n n n

Thi Th Th Thi Thii Thihih Th

T s cs cs css cs cs css s cccchaphaphahhaphaphaphaphappttetetteterttttertert in ininininininnnntrotrotrtrotrtrotroror ducdducducdducducducducducuuucuceeseses ese benbbbenbenbenene zodzozozodzzodzodzododdiiaziaazzepiepipiiine nnene e useusee an ananaanana d id idd id iits ts tststststs ttsts assasassassassasasssociateociociocicataaateateataed pd pd pd d pprpprobrobrobror blelemlelemememems.sss. s. s AltAAltAltAltAltthouhhoughhhohouhoough gh gh gh hhhhhh pha

phaha pha pha pha pha pha pha p

p rmarmarmrmarmamamaaaacolcococolcoloologiogiogioogogicalcacacalcalcalcalcalaalal tr tr tr trtrtrtrtrtreateeeateeateateateeatatmenmmenmenmenmenmenmenmenent wt wtt wtt wt wwithithithithth bethhh be b bbbbenzozoooddiadiazepddiiazeppineineineeees css cs cs ccccanan ananananannn bbebe be be bebebe e effeffecteffeffefffectectectttiviveiiveve anveveve anananananannd mdd md md mmmayay ayayay ay y bebebe bebebe e eeeee tthethethethehehehe beee b be bbebebestsst st ststsssstt tre

tre tre tre tre tre

treatmatmatmatmatmatmtmenttmtt entententntt in in iniiinininn cececcec rtartartartartataaaainininiiinininin nncatcaccccacatcatcaattegoegoegoegogogorooories orierierierieries os os s oss offf pf pf pf f fpppatiatienennntntntntntsss,s, s inin ngengengennneraneraeraeraeraraalaal, l, l, l, ll,l,, chrccccchrchrchrchrchrhonoonionionononicccc uc uc ucc uc ussese sesese se seeofof oofof ofof ofbenbenbebenbenbebe zodzozodzodzodzodiaziaziaazazazzepieepiepiepinesnennenesnesneeses isisisisisiiss n n notnononott t des

des deses des de d d

desirairirairaiirairairarabbleblebleblebleblblebee. I. I. I. I. In aIIInnnn annn an addidddiddiddddddiddtiotiotiotiotiotion, n, nn, nnn, n,ththttthithithihhiss cs cs cchapcccchaphaphaphhaphaphaphapapapppppteteter dtertertertererererrddedeescrscriscscrscrcrcrribibeiibess thhe heeeeeee stue stustustusstutut diedies tdiediediediediediedieieess tsss ts tss ts ttthathahathahahathataat wewewewewewewerererererere econcconconconconconoo ducdudduducducdududucducducucu tedtedtedede to totoooo ino ininnnvesvvevesvesvesvesestigtigtigtigtigtigtigateaateateateatea the

the thehehee

theheheheh pr prprppprprprobloblooboblobloblobloblbllememem emem ememem em m m of of of ofoofofchrcchchrchrchchrchchrchrhhrronionioniononininnc uc uc uc uc uc uc use se sesseee oof oof ofof of off bebbebenbenbebebeenee zodzododododddiaiiaiiaziaazepiepepinesnesnes freses fr frffrfrfrfrfrfrorromomom omomom m a haa ha ha ha haa haa healeaealealalath ththth th thhh psypsypsypspsypsysysyychochochocchohohhohologloglologicloogogicaicaicaicaicaicaicccaal pl pl pl pl pl l pl pll persersersersersrr ppecppecpecpecpecpecpeceecctivtivtivtitittiive. e. e.

Thi T Thi Thi T Th

Thihs csss cs css ccchaphaphaphaphaphapapaptpttetertettertertertterere a alalso alalalalalsoso sosososososo desdedescridedesdesescricrcriccrirbesbesbesbesbesbeses theses thttthtthhe deeee de de ddddeveeveevelopeveloploploploplopopopmenoopopooo menntt t ooof aoof af af aaaaaaaan in inn in in in in n iintenterventenntenntenteteerververververrvvevveentinntion ntintintion ononnn nn tto to tototo ooooredreredredreducuceuceuceucecececec ch chchchchchchchhhronronronrronrr nnic ic icic ic c useuuseuseusesesee of of oof ben

ben be ben ben be be

be zodzodzodzozodzodzodzodododdiaziaziaziaziazazzepzzepiepiepiepiepeppppinnesnnenesnesneneseese by by by bybybbybybyb us usususususu iingingingingngng thththththhhhee Precee Pe Pe Pe Pe PPPPrerecrecrerereceecedeedeedeedeededee/Pr/Pro/Pr/Pr/Pr/Pr//Pr/PrProceoceoococo edeeded ededdd d mmomodmodmomodmomodmomo el el el ell laasasasasasasas asassa ta a taa taa ta ta ta ttthheoheoheoheoheoeoeoooretrerretreretrrretretr tticicaicaicaicacacccal fllll fl fl fl fframrramramraaamamamewomeeewoewoewoewoork.rk.rk.rkrk.k

CHAPTER 1

Chapter 1

Benzodiazepine use and its associated problems

Benzodiazepines

Benzodiazepines are drugs with sedative, hypnotic, anxiolytic, anticonvulsant, amnestic and muscle relaxant properties (1). Benzodiazepines are often prescribed for short-term relief of severe, disabling anxiety or insomnia.

All benzodiazepines have the same effect in the body and can therefore be used as a hypnotic (benzodiazepine used to treat insomnia) or anxiolytic (benzodiazepine used to treat anxiety). They are believed to act on the GABA receptor, the activation of which dampens higher neuronal activity. A large variety of benzodiazepines are available and they differ in the speed at which they are metabolized (in the liver) and eliminated from the body (in the urine). The speed of elimination is important in determining the duration of its effects. With most benzodiazepines, noticeable effects usually wear off within a few hours. Nevertheless, the active substances, as long as they are present, continue to exert subtle effects within the body. Thus, there are a large number of benzodiazepines, but every benzodiazepine can be used for the relief of anxiety as well as insomnia (2). However, in practice it turns out that Diazepam is mainly used to relieve anxiety, nervousness and tension, while Nitrazepam is mainly used to treat insomnia. These two types are the most commonly used benzodiazepines (3).

Prevalence

The use of benzodiazepines increases with age: half of the users are younger than age 65, twenty-five percent are between 65 and 75, and twenty-five percent are older than age 75. The prevalence of use among women is twice as high as the prevalence of use among men. Eighty per cent of benzodiazepines are prescribed by general practitioners and of these benzodiazepine prescriptions, more than eighty per cent are refills (4). Refills are repeat-requests handled by the medical staff of the general practitioner without consulting the general practitioner or medical specialist.

Benzodiazepines are one of the most prescribed classes of drugs in Western countries. The total number of benzodiazepine users in 1998 in the Netherlands was estimated at almost 1.9 million. This corresponds with an annual prevalence of 12.2% (5). Of these users, more than a third use benzodiazepines on a chronic basis. In other words, 3 to 4 per cent of the population uses benzodiazepines chronically (5). The definition of chronic use is not univocal (6). According to the guidelines for general practitioners (7), chronic use is defined as daily use of benzodiazepines for more than three months. Other countries also have to contend with widespread and long-term use: 500,000 to 1 million in the UK, 4 million in the US and several million worldwide (8). The latest report (9) is that the number of benzodiazepine prescriptions has increased by two per cent in the 2001–2006 period. There is a common understanding that the extent of chronic benzodiazepine use needs to be reduced (9). This thesis will therefore focus on chronic benzodiazepine use, with chronic use defined as daily use for more than 3 months.

Chapter 1 Characteristics of a benzodiazepine chronic user

Most patients who take benzodiazepines on a chronic basis are elderly females.

Most of them are taking benzodiazepines as hypnotics. Chronic users are mainly patients having physical problems, patients having a mental illness or patients abusing other substances (10;11). Kan et al. (12) identified risk factors for becoming a chronic user and found that patients with a higher initial benzodiazepine dose, and a longer duration of benzodiazepine use, and younger patients were more likely to become chronic users. The substance dependence criteria for benzodiazepine dependence of the DSM-III-R and ICD-10 classifications were used. Also patients of non-native cultural origin or having a lower level of education were more likely to become chronic users of benzodiazepines. Personality characteristics such as fearfulness, passivity and dependency are also associated with chronic use of benzodiazepines (13).

Problems associated with chronic benzodiazepine use

Only short-term treatment with benzodiazepines appears to be effective in the treatment of sleeplessness and anxiety. Chronic use of benzodiazepines is not only ineffective; it is even associated with several negative health consequences, such as dependence, cognitive impairment, falls and accidents, and high expense. These adverse effects will be described in that order.

Dependence

First of all, patients can become dependent. There is however little consensus about the definition of dependence. Kan et al. (14) has looked at the DSM- III-R substance abuse criteria, and the indications are that 40% of outpatient benzodiazepine users are dependent (14). The criteria for substance dependence include tolerance, escalation of dosage and withdrawal symptoms in the case of stopping. Tolerance to benzodiazepines develops at different rates in varying degrees for various actions. Tolerance to hypnotics, for example, develops rapidly, within a few days or weeks in cases of regular use (15). Although some studies cast doubt on this (16), tolerance to anxiolytics has also been reported, but this develops less rapidly (17).

Escalation of dosage also occurs. Clinical studies show that a considerable proportion of patients using hypnotics and anxiolytics gradually increase their dosage on their own, sometimes exceeding the safe levels (18;19).

Benzodiazepine withdrawal symptoms have also been demonstrated.

The following withdrawal symptoms can occur: rebound anxiety, rebound insomnia, depression, dizziness, tremor, muscle pain, sweating, blurred or double vision or in extreme cases seizures (20;21). Besides physical dependence, psychological dependence is likely to occur from chronic use of benzodiazepines. A study among long-term hypnotic users showed that benzodiazepine users indicated that the sleep medication greatly improved their quality of sleep. The objective results, however, did not support this.

There were no significant differences between untreated sleep complainers and treated sleep complainers regarding sleep duration and sleep latency (22). Other psychological aspects of dependence have also been reported

Chapter 1

such as drug-seeking behaviour and continued use despite the adverse effects (20;23).

Cognitive impairment

Secondly, long-term use has been associated with cognitive impairment. A meta-analysis of thirteen studies which compared long-term benzodiazepine users with controls revealed that moderate to large deficits in different cognitive domains occur (24). For example, Westra and colleagues (25) investigated the influence of benzodiazepines on memory performance.

They compared sixteen daily users of benzodiazepines diagnosed with a panic disorder to sixteen age- and education-matched, non-medicated panic disorder patients. Both groups were assessed on the basis of a memory task.

The results indicated that benzodiazepine users showed significantly poorer memory performance than did controls. In another study (26), chronic use of benzodiazepines caused anterograde amnesia. Anterograde amnesia is a form of memory loss in which new events are not transferred from short- term memory to long-term memory. These patients could not remember what had happened or what was learned. After withdrawal from chronic use of benzodiazepines, patients were still cognitively impaired when compared with control groups. Other studies have shown that patients do not return to levels of functioning that matched benzodiazepine-free controls (27;28).

The cognitive effects might improve in the long run, since the studies did not include long follow-ups.

Falls and accidents

Although there is a study which does not find an association between the use of benzodiazepines and accidents (Leveille et al (29) found no evidence of a dose-related effect with benzodiazepines: use of benzodiazepines had little association with increased risk for injurious collisions), most studies do.

It is known that chronic use of benzodiazepines leads to sedation and has a relaxant effect on muscles, and this can lead to falls, fractures and road traffic and other accidents (30-32). The elderly are most vulnerable to these effects, especially if taking multiple medications (33). Benzodiazepines are on the whole safe drugs, even if taken in an overdose (34). Nevertheless, some studies have reported that benzodiazepines can be lethal in overdose (35;36) .

High expense

Benzodiazepines are low-priced drugs: the medication price for one tablet of Nitrazepam of 5 milligrams, for example, is €1.08. Due to the high prevalence rate, however, the costs in 1998 were estimated at 145 to 172 million Euros (37). When looking at the period 1993–98, there was a mean annual increase of 2.1% which resulted in the seventh highest annual increase in drug costs in the Netherlands (5). Looking at the most recent figures, the prescriptions for Oxazepam (2.919.000) in 2006 compared to 2005 have also increased by 2.1 % (38).

Chapter 1 As mentioned above, chronic use of benzodiazepines can cause dependency,

cognitive impairment, falls and accidents, which results in high costs for the health care system. Because of these problems associated with chronic use of benzodiazepines and because long-term use results in lack of efficacy due to tolerance, there is an urge to reduce the chronic use of benzodiazepines.

Which treatment methods are used in the Netherlands in order to reduce the amount of benzodiazepines prescribed?

Cessation of benzodiazepine use – treatment methods

Different treatment strategies are known in order to decrease the amount of chronic use of benzodiazepines. In a meta-analysis, Oude Voshaar et al.

(39) divided the available interventions into two different strategies: minimal interventions and systematic discontinuation programs. Minimal interventions, on the one hand, invite patients to quit their long-term benzodiazepine use on their own by making them aware of the negative consequences. Systematic discontinuation programs, on the other hand, are more intensive interventions in which patients gradually discontinue their doses under the guidance of a general practitioner or pharmacist. The main finding of the meta-analysis of Oude Voshaar (40) was that minimal interventions are effective strategies for reducing benzodiazepine consumption. Three minimal interventions were investigated having a pooled odds ratio of 2.8 relative to patients receiving usual care. Only one systematic discontinuation program was evaluated. This study (41) examined the effectiveness of a dose-reduction program in a randomized controlled trial. Three arms were compared: a dose reduction program, a dose reduction program combined with cognitive therapy and a control group receiving regular care from the general practitioner. It turned out that the two experimental groups showed greater reduction than the control group (respectively 62% and 58 % versus 21 % of the control group), with the finding of an odds ratio of 6.1 There were no significant differences between the two experimental groups. A problem of this extended discontinuation program was that the participation rate was low. Only 46 % completed the program.

Although these strategies have been shown to be effective (39;42), they are often not offered to patients (43;44). It appears that general practitioners or pharmacists do not discourage their patients from chronically using benzodiazepines by educating them about the disadvantages of chronic use of benzodiazepines, since 80% of prescription refills are handed out by the assistant instead of by the general practitioners or pharmacists seeing the patient themselves (4). In other words, chronic benzodiazepine users are not stimulated to reduce or quit their benzodiazepine intake with the help of the general practitioner or pharmacist. One reason which has been frequently reported is that general practitioners and pharmacists simply lack the time (45). A study in Denmark recently showed (46) that the reorganization of prescription patterns proved to be significantly easier than practitioners had expected. The intervention consisted of helping the general practitioner follow the protocol regarding the prescriptions of benzodiazepines (i.e. prescription only for 1 month and only following consultation (telephone consultations

Chapter 1

were eliminated). After this intervention, use of benzodiazepine hypnotics was reduced by 46.5 %, and use of anxiolytics was reduced by 41.7 %.

Education is also important because it will result in more satisfied patients, patients will have a better understanding of the pros and cons of medication, and it will result in more compliance to treatment (47). It is also known that when general practitioners or pharmacists do educate, they can play a vital role in changing patients’ attitudes towards medicine use. For instance, it has been shown that pharmacists can play an important role in changing drug attitudes of depressive patients (48). Thus, we can conclude that educating the benzodiazepine user can have positive results in terms of the aim of reducing the amount of benzodiazepines.

The above shows the following two important notions. Namely, first of all, it appears that patients can be better educated in order to help them reduce chronic use of benzodiazepines. Secondly, general practitioners and pharmacists can educate their patients more often, since we know that 80

% of the prescriptions for benzodiazepines are refills. Thus, these patients are not seen by their general practitioners. Because of this, and because of the adverse effects and the lack of efficacy of benzodiazepines and the high costs of continued benzodiazepine use, there is a need to develop a tool that lightens the workload of these health practitioners, while at the same time educating patients about the disadvantages of benzodiazepine use. This tool might well be a computerized patient education program: a computer program that automatically produces educational letters. Among other health behaviours, computerized tailored information has been shown to lead to more behavioural changes as compared to no information and to similar but non-tailored interventions (49-52). Computer tailoring is aimed at a specific person, based on determinants of behavioural change, and is composed for one person in particular. Tailored information, therefore, mimics the process of individual counselling and feedback, to the extent that it can be provided through a written text. The expertise of the counsellor is documented in the computer program. In other words, computerized patient education involves adaptation of the content information to relevant patient characteristics, while at the same time it can be applied on a large scale. Computerized patient education brings with it, on the one hand, personalization, and on the other hand, applicability to large groups. If such a tool proved to be effective in terms of reducing benzodiazepines, it could be broadly implemented in the Dutch health care system without a great deal of effort on the part of the general practitioner or pharmacist.

A key to a solution

The purpose of this thesis is to tackle the problem of chronic use of benzodiazepines by increasing and improving education by developing a computer program which automatically produces educational letters without the interposition of the health practitioner. In order to produce educational letters with such a computer program, we have to use information which it is known will result in behavioural change. In order words, the educational letters need to contain information aimed at increasing motivation and advising

Chapter 1 patients about how to reduce or quit their chronic use of benzodiazepines.

However, it is necessary to use a theoretical framework that has been successful in developing interventions.

The Precede/Proceed model

Health educators have recognized the importance of careful theory-based intervention planning, because the effectiveness of health promotion interventions is influenced by the quality of their planning (53). Thus, in order to develop such a computer program which produces educational letters, it is important that it is based on a sound model. The project prescribed in the present thesis was therefore developed according to the principles of the Precede/Proceed model. A simplified version of the Precede/

Proceed planning model (54) was used as the framework for this thesis. The Precede/Proceed model has proven to lead to significant improvements in interventions for smoking cessation (55), in health promotion campaigns (56) and in intervention with pharmacists to encourage patients to regularly use their hypertension medication (57). The model consists of two phases.

The Precede part describes several phases in analyzing the health problem.

The Proceed phase focuses on intervention development and implementation (see figure 1).

Precede Proceed

Problem analysis

Risk behavior analysis

Determinant analysis

Intervention development

Intervention implementation

Figure 1 Precede/Proceed Model for planned health promotion (43)

Phases I and II – Problem analysis and risk behaviour analysis

According to the Precede/Proceed model, the first step (i.e., Phase I – problem analysis) in health promotion planning is the identification of a health problem that is serious and prevalent enough to justify spending time, money and other resources on developing and implementing an intervention.

In the second step (i.e., Phase II – risk behaviour analysis), specific risk factors for the health problem in question should be identified, as should the groups of people who are exposed to these risk factors. So far, regarding these two phases, this chapter has shown that benzodiazepine use is a health problem which has serious negative consequences on health. This chapter has also shown that three groups are involved in the problem of chronic use of benzodiazepines: general practitioners, pharmacists and patients.

General practitioners and pharmacists are involved in chronic benzodiazepine use because they often offer insufficient education and treatment methods.

Patients are the ones who ultimately make the decision about using the prescribed drugs or not. To that end, Phases I and II have been described in this chapter, and we therefore proceed with Phase III.

Chapter 1

Phase III – Determinant analysis

The third step (i.e., Phase III – determinant analysis) in planned health promotion is to investigate the psychosocial determinants of chronic benzodiazepine use. In order to influence chronic use of benzodiazepines successfully, it is necessary to gain insight into the psychosocial determinants of the target groups when engaging or persisting in that particular behaviour.

As mentioned in the previous section, there are three different parties involved in benzodiazepine use, namely general practitioners, pharmacists and patients. Psychosocial determinant analyses will be conducted among these groups. First of all, it is important to know which psychosocial determinants are related to the intention of the general practitioners and pharmacists to educate their patients about the disadvantages of benzodiazepine use (Chapter 2).

And in order to educate the patient properly, it is also important to know the determinants related to benzodiazepine use (Chapters 3 and 4). The determinants that turn out to be related to benzodiazepine use and cessation can then be used in the development of the computer program which produces tailored patient education letters (Phase IV). The tailored letters then contain information developed to change those determinants which are related to benzodiazepine cessation. In order to find out which determinants we have to target in the tailored letters, we used in this thesis determinants which are derived from two health theories, determinants which are frequently used to explain health behaviour (52;53).

Which determinants?

The determinants studied in this thesis have been derived from the Theory of Planned Behaviour (58) and Social Cognitive Theory (59). These two theories have proven to be successful in explaining a number of different health behaviours (60). The two theories assume that the most important determinant in behaviour is a person’s intention to change his or her behaviour.

This behavioural intention represents a person’s motivation in the sense of his or her plans to actually change behaviour. Intention is, in turn, assumed to be most directly determined by three types of cognitive factors: attitudes, social influences and self-efficacy. Self-efficacy expectations are people’s perceptions of the extent to which they are able to successfully accomplish a specific task (e.g., to cope with anxiety without benzodiazepines). Attitudes are the overall evaluations of the behaviour by the individual based on beliefs and evaluations and, lastly, social norms consist of a person’s perception about whether significant others think he or she should perform a certain behaviour. Figure 2 visualizes this model.

Chapter 1

Attitude

Intention Behaviour

Self-efficacy

Social norm

Figure 2 The main determinants derived from Theory of Planned Behaviour and Social Cognitive Theory (58;59)

Thus, the three concepts (attitude, self-efficacy and social norm) predict one’s intention to perform a certain kind of behaviour. Intention is the major predictor of behavioural change. The different determinant analyses described in Chapters 2 and 4 used the above theory in order to find out the factors which are responsible for predicting the intention to educate and benzodiazepine cessation.

Besides the determinants described above, in chapter 3 we used another theory in explaining benzodiazepine use. A psychological model that has often been used to explain illness behaviour is the Common Sense Model (CSM) of Leventhal (61). According to the CSM, illness behaviour can be explained by patients’ own perceptions of their illness. The illness perceptions of the CSM include five key attributes: identity, cause, consequences, control or cure, and timeline. In the present study we will assess the illness perceptions with regard to the illness (or mental health problem) that motivated the initiation of the use of benzodiazepines. Identity refers to the specific set of complaints that signal the specific illness. Cause refers to a person’s beliefs about the origin of the illness that motivated the initiation of benzodiazepine use. Consequences are ideas about the short and long-term outcomes of the illness. Control or cure refers to beliefs about the extent to which one can control or cure the illness. Lastly, timeline concerns ideas about whether the illness is acute or chronic in nature.

Studies that examine the CSM model have provided support for the hypothesis that a strong illness identity (the attribution of many complaints to the illness), as well as a belief in a long duration for and serious consequences of an illness, have a negative effect on the well-being of patients (62;63). In the case of benzodiazepine use, it could be the case that illness perceptions do apply for benzodiazepine users, in that perceptions lead to reduced well-being which will ultimately result in drug seeking behaviour, like benzodiazepine use. In addition, patients who perceive their illness as more serious (patients who attribute more complaints to their illness, rate the consequences as more severe, perceive less control over their illness, and think that the illness will last a long time) use more benzodiazepines as a coping behaviour. Therefore, in the research presented in chapter 3, we have assessed illness perceptions with regard to illness “as it would be were they

Chapter 1

not to use benzodiazepines.” Knowledge of the illness perceptions held by patients can also be used for the development of an intervention to stimulate patient education. A better understanding of the perceptions of patients may improve the quality of decision-making with regard to the most desired and appropriate treatment for a patient’s problems. These illness beliefs have been studied in chapter 3.

Phase IV – Intervention development

Phase IV in the Precede/Proceed model deals with intervention development (Chapter 5). On the basis of the results of the previous phases, an intervention can be developed which is aimed at changing behaviour. To capture the problem of chronic benzodiazepine use, three groups have to be targeted: general practitioners, pharmacists and patients. Interventions can be developed to target these three groups. However, this thesis will only focus on changing the behaviour of the patient. The results of chapter 2, which deals with the determinants related to the intention of the general practitioner and pharmacist, will not be used in the intervention. Changing behaviour can be achieved by changing the psychosocial determinants, that is, those determinants which have proven to be related to benzodiazepine use and cessation. Thus, the determinants that turned out to be related in Phase III described in chapter 3 and 4 are used for Phase IV: the development of the intervention. The next step is to describe the development of the intervention, computer-tailored education, in more detail.

Computer tailored education

Computer tailored education is aimed at a specific person and based on determinants of behavioural change (as described in phase III (chapters 3 and 4)). These determinants are assessed for everyone individually by means of a questionnaire. The computer-tailoring intervention is developed using the method of Dijkstra & De Vries (64). The tailoring included three mechanisms that have the potential to be effective; personalization, feedback and adaptation. Personalization was applied by starting with the participant’s surname (e.g., “Dear Ms. Brown,’) and by mentioning twice in the text the type of benzodiazepine that the individual used. Feedback was provided on statements made by patients in the individual assessment. For example:

“You think that benzodiazepines really help you to get a good night’s sleep.”

Feedback was also given on the determinants, which were measured in Phase III of the Precede/Proceed model (i.e. attitude, self-efficacy and social norm). Adaptation implies that information was adapted to the individual. For example, if self-efficacy is low, then the participant receives a message about how to increase his or her self-efficacy.

The computer program generates the tailored education letters. The core of this program consists of different sets of decision rules. A decision rule is a connection between an answer to an item in the questionnaire and a message text. For example, if self-efficacy is low, then the participant receives a message text about how to increase his or her self-efficacy. The computer program combines all these different message texts into one coherent intervention message and offers it in an attractive layout. Depending on

Chapter 1 the individual item scores, the letters then contain specific combinations of

information based on the different determinants (see also Figure 3).

Each letter started with an introduction explaining the goal and the rationale of the information. Subsequently, the three main determinants of discontinuing usage were addressed. The information was designed to: 1) increase the perceptions of the positive outcome expectations of discontinuing benzodiazepine use (for example, it was argued that patients may function better cognitively and may evaluate themselves more positively); 2) lower the perceptions of the positive outcome expectations of the use of benzodiazepines (this was done by explaining the development of tolerance and a possible placebo effect), and 3) increase self-efficacy expectations with regard to discontinuing usage (this was done by offering several skills to reach abstinence, such as making a plan to cut down benzodiazepine use and by offering alternatives in order to cope with worrying thoughts). Thee three mechanisms will also increase well-being, which will ultimately result in better decision-making by the patient

In this project, two different interventions will be examined: single tailored letters and multiple tailored letters. The single tailored letter intervention consisted of one letter of 5 to 6 pages of information (approximately 1200 words) in which all of these three psychological determinants were addressed in the above order of presentation. The multiple tailored letter intervention consisted of three letters of about 3 pages each (approximately 400 words),

Tailored Education:

Input

Computer program

Output

Questionnaire

Decision rules Messages

Tailored education

Figure 3 The process of tailored education

Chapter 1

sent at intervals of one month. In the multiple tailored intervention, the first tailored letter was designed to increase the perceptions of the positive outcome expectations of discontinuing benzodiazepine usage and to lower the perceptions of the positive outcome expectations of the use of benzodiazepines. The second tailored letter was designed to increase self- efficacy expectations with regard to discontinuing usage, while the content of the third letter provided more skills for discontinuing usage, or provided a summary of the information in the first two letters, depending on the individual needs detected in the third assessment. In addition, in the introduction of the second and third letter, participants were provided with progress feedback:

individual changes in benzodiazepine use were mentioned.

Phase V

Phase V deals with intervention implementation. If the intervention proves to be effective, the intervention will be ready for implementation. Before that, an implementation study is needed to find out how the intervention can best be implemented. Effective health education and promotion programs will have little impact if they are never used or if they are discontinued while still needed to create the desired health impact. In chapter 6, the issue of implementation of the computer program for tailored patient education will be briefly mentioned in Chapter 6. An inventory was conducted among different health care organizations in the Netherlands to find out the possibilities. A company can for example put the computer program on their website and invite their insured, for example, to visit their website. A qualitative study among general practitioners and pharmacists was conducted to find out if both groups are positive about the intervention and what would be the best way according to them to implement it.

Outline of this thesis

The focus of this thesis is twofold. The first part entails capturing the benzodiazepine problem by focusing on three different parties: pharmacists, general practitioners and patients. The pharmacists’ viewpoint and the general practitioners’ viewpoint on benzodiazepine use will be described in Chapter 2. In this chapter, a cross-sectional survey using a questionnaire was conducted among 339 general practitioners and 149 pharmacists. This study investigated which psychological factors predicted the intention to educate their patients about benzodiazepine use. The patients’ viewpoint will then be described in Chapters 3 and 4 and these results will be used in the intervention. Chapter 3 deals with the perceptions of the patients about the reasons why they are using benzodiazepines (the illness beliefs), while Chapter 4 focuses on the psychosocial determinants of benzodiazepine cessation. More specifically, Chapter 3 describes the role of illness beliefs on benzodiazepine use in a longitudinal study among 356 benzodiazepine users, while Chapter 4 examines the determinants of benzodiazepine cessation in a longitudinal study among the same group of participants as described in Chapter 3.

Chapter 1 In the second part of this thesis, the solution aimed at the reduction of

chronic use of benzodiazepines in the Netherlands will be examined, namely computer-generated tailored education letters about benzodiazepines. The results of this study will be presented in Chapter 5. This chapter describes a randomized-controlled trial among 508 benzodiazepine users in order to examine the effectiveness of two types of computerized patient education letters about benzodiazepines. Finally, Chapter 6 describes the implementation study which was conducted in order to find out the best way to implement the tailored education program (phase V of the Precede/Proceed model). This chapter also summarizes the main findings of this thesis, and the implications are discussed. Lastly, the limitations of our study and suggestions for future research are presented in this chapter.

Because most of the chapters were written to be published as research papers, they are self-explanatory outside the context of this thesis. Due to this structure, some information may be redundant or may overlap. Table 1 provides an overview of the studies that were conducted in the context of the present thesis.

Table 1 Overview of the studies presented in this thesis

Chapter Design Methods Sample Study objective

2 Cross-sectional Questionnaire 333 GPs

135 Ps Determinants of intention to educate about benzodiazepines 3 Longitudinal Questionnaire Same

sample of 356 patients

Role of illness beliefs on benzodiazepine use

4 Longitudinal Questionnaire Determinants of benzodiazepine cessation

5 RCT Questionnaire 508

patients Effects of computer-generated tailored education about benzodiazepines Note. GPs = General practitioners Ps = Pharmacists

Acknowledgements

The studies presented in this thesis were financially supported by the Dutch Council for Health Insurance.

References

(1) Coenen AML, Knuistingh Neven A. Benzodiazepinen [Benzodiazepines]. In:

Knuistingh Neven A, editor. Modern Sleep Medicine. Alphen aan den Rijn: Van Zuiden Communications BV; 1999. p. 157-66.

(2) Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2006;18(3):249-55.

(3) Matalon A, Yinnon AM, Hurwitz A. Chronic use of hypnotics in a family practice-- patients’ reluctance to stop treatment. Fam Pract 1991;7(4):258-60.

(4) Stichting Farmaceutische Kengetallen. Data & Feiten 2005. 2005.

(5) GIP signaal - Gebruik van benzodiazepinen 1993-1998 [GIP-signal - Use of benzodiazepines 1993-1998]. Amstelveen; 2000.

(6) Zandstra SM. Different study criteria affect the prevalence of benzodiazepine use.

2002.